{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:21:01Z","timestamp":1767831661504,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"vor","delay-in-days":1293,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.jchf.2014.04.012","type":"journal-article","created":{"date-parts":[[2014,10,6]],"date-time":"2014-10-06T15:46:11Z","timestamp":1412610371000},"page":"545-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["\u201cTriple Therapy\u201d of Heart Failure With\u00a0Angiotensin-Converting Enzyme Inhibitor, Beta-Blocker, and Aldosterone Antagonist May Triple Survival Time"],"prefix":"10.1016","volume":"2","author":[{"given":"Graham D.","family":"Cole","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheetal J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabeela","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Barron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire E.","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamil","family":"Mayet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrel P.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2014.04.012_bib1","unstructured":"National Heart Failure Audit 2010. Available at: http:\/\/www.wales.nhs.uk\/sites3\/Documents\/490\/National%20Heart%20Failure%20Audit%20Report%202009%2D10.pdf. Accessed January 21,\u00a02013."},{"key":"10.1016\/j.jchf.2014.04.012_bib2","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinternmed.2010.270","article-title":"Lack of improvement in outpatient management of congestive heart failure in the United States","volume":"170","author":"Banerjee","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jchf.2014.04.012_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/CIRCULATIONAHA.106.669101","article-title":"Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes","volume":"116","author":"Gislason","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2014.04.012_bib4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1200\/JCO.2004.04.095","article-title":"Cancer patient preferences for communication of prognosis in the metastatic setting","volume":"22","author":"Hagerty","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jchf.2014.04.012_bib5","unstructured":"Engauge Digitizer\u2013digitizing software. Available at: http:\/\/digitizer.sourceforge.net Accessed on September 9, 2012."},{"key":"10.1016\/j.jchf.2014.04.012_bib6","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1016\/j.ijcard.2013.05.068","article-title":"Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information","volume":"168","author":"Barron","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2014.04.012_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jacc.2007.11.016","article-title":"Task Force 8: training in heart failure endorsed by the Heart Failure Society of America","volume":"51","author":"Young","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2014.04.012_bib8","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1093\/eurheartj\/eht234","article-title":"ESC core curriculum for the general cardiologist (2013)","volume":"34","author":"Gillebert","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2014.04.012_bib9","unstructured":"Joint Royal Colleges of Physicians Training Board. Speciality Training Curriculum for Cardiology. August 2010. Available at: http:\/\/www.gmc-uk.org\/Cardiology_curriculum_2010.pdf_32485140.pdf. Accessed January 2,\u00a02014."},{"key":"10.1016\/j.jchf.2014.04.012_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2014.04.012_bib11","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1016\/j.jacc.2013.07.080","article-title":"Quantification of survival gain from cardiac resynchronization therapy: nonlinear growth with time, and greater gain in low-risk patients, make raw trial data an underestimate of real-world behavior","volume":"62","author":"Finegold","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2014.04.012_bib12","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2014.04.012_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1388-9842(01)00144-1","article-title":"Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure","volume":"3","author":"Shibata","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2014.04.012_bib14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials","volume":"30","author":"Ezekowitz","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2014.04.012_bib15","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCOUTCOMES.112.966853","article-title":"Why does primary angioplasty not work in registries? Quantifying the susceptibility of real-world comparative effectiveness data to allocation bias","volume":"5","author":"Sen","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jchf.2014.04.012_bib16","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.105.584102","article-title":"The Seattle Heart Failure Model: prediction of survival in heart failure","volume":"113","author":"Levy","year":"2006","journal-title":"Circulation"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177914002704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177914002704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T15:50:11Z","timestamp":1538149811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177914002704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S2213177914002704"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2014.04.012","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cTriple Therapy\u201d of Heart Failure With\u00a0Angiotensin-Converting Enzyme Inhibitor, Beta-Blocker, and Aldosterone Antagonist May Triple Survival Time","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2014.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}